The promising trajectory of autism therapeutics discovery

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Pharmacological interventions for neurodevelopmental disorders are increasingly tractable. Autism is a neurodevelopmental disorder that affects approximately 1% of the population. Currently, the standard of care is early behavioral therapy. No approved medical treatments for the diagnostic symptoms are available. Strong evidence for genetic causes of autism implicates proteins that mediate synaptic transmission and structure. Mouse models with targeted mutations in these synaptic genes display behavioral symptoms relevant to the social communication abnormalities and repetitive behaviors that define autism spectrum disorder (ASD), along with biological abnormalities in synaptic physiology and morphology. As we discuss here, promising pharmacological targets, emerging from the mouse model studies, are now being pursued in early clinical trials. Thus, a high-prevalence disorder that was previously considered to be medically untreatable is now moving into the therapeutic arena.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalDrug Discovery Today
Issue number7
StatePublished - 2014

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'The promising trajectory of autism therapeutics discovery'. Together they form a unique fingerprint.

Cite this